Home Ingredients Ipriflavone
Bone Health

Ipriflavone

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Ipriflavone is a synthetic isoflavone derivative (7-isopropoxyisoflavone) developed in the 1980s for osteoporosis. Distinguished from natural isoflavones by no significant estrogenic activity — bone effects without estrogenic concerns. Used extensively in Japan, Italy, and Hungary as prescription osteoporosis medication. Mixed clinical evidence; large 4-year IPRI study failed to show fracture reduction and revealed lymphocyte concerns — limiting current use.

Studied Dose 600 mg/day in three divided doses (200 mg TID with meals)
Active Compound Ipriflavone (7-isopropoxyisoflavone)

Benefits

Bone Mineral Density Support (Mixed Evidence)

Earlier Italian, Japanese, and Hungarian trials showed ipriflavone 600 mg/day modestly improved BMD in postmenopausal osteoporosis. However, the larger, longer 4-year IPRI study (n=474) failed to confirm fracture reduction or BMD benefit vs placebo — significantly weakening the evidence base.

Supported by Trial 1, Trial 2

Non-Estrogenic Mechanism

Distinguishes ipriflavone from natural isoflavones (genistein, daidzein) which have estrogenic activity. Theoretical advantage for women avoiding estrogenic effects (e.g., breast cancer survivors). Mechanism: direct stimulation of osteoblasts and inhibition of osteoclasts without estrogen receptor activation.

Supported by Trial 1

Calcitonin Enhancement

Ipriflavone enhances calcitonin secretion and effect — calcitonin reduces bone resorption. One mechanism for bone effects.

Supported by Trial 1, Trial 2

Calcium Combination Effects

Some evidence that ipriflavone is more effective when combined with calcium supplementation — typical clinical use is ipriflavone 600 mg + calcium 1,000 mg + vitamin D.

Supported by Trial 1, Trial 2

Adjunct in Postmenopausal Bone Health

Used as adjunct alongside calcium/vitamin D in some European integrative protocols. Modern use limited by IPRI trial findings and lymphocyte concerns.

Supported by Trial 1

Mechanism of action

1

Direct Osteoblast Stimulation

Stimulates osteoblast proliferation and bone formation marker expression — independent of estrogen receptor mechanism.

2

Osteoclast Inhibition

Reduces osteoclast number and activity — inhibits bone resorption.

3

Calcitonin Modulation

Enhances endogenous calcitonin secretion; potentiates calcitonin effects on bone.

4

Non-Estrogenic Activity

Despite being an isoflavone derivative, ipriflavone (and its main metabolite daidzein — wait, daidzein IS estrogenic) — actually one concerning aspect is that ipriflavone is metabolized partly to daidzein, which IS estrogenic. So the 'non-estrogenic' positioning is partially compromised by metabolite considerations.

Clinical trials

1
Ipriflavone for Osteoporosis — IPRI Study

Large 4-year clinical trial of ipriflavone 600 mg/day vs placebo in 474 postmenopausal women with osteoporosis.

474 postmenopausal women.

Failed to show fracture reduction or BMD benefit vs placebo. Additionally: reduction in lymphocyte counts in 13.2% of ipriflavone group vs 4.0% in placebo — concerning safety signal. Significantly weakened ipriflavone evidence base; led to reduced clinical use.

2
Earlier Ipriflavone Trials — Pooled Evidence

Earlier short-term Italian, Japanese, Hungarian trials of ipriflavone for osteoporosis.

Pooled across earlier trials.

Modest BMD improvements in 1-2 year trials. Not replicated in larger, longer IPRI study. Highlights importance of longer follow-up and larger sample sizes for chronic disease interventions.

Side effects and drug interactions

Common Potential side effects

GI distress (most common — nausea, abdominal pain, dyspepsia).
Lymphocyte reduction — IPRI study showed 13.2% incidence vs 4.0% placebo; reversible upon discontinuation; warrants monitoring.
Headache.
Dizziness.
Skin reactions / rash.
Liver enzyme elevations rare.
Theoretical estrogenic effects via daidzein metabolite (modest).

Important Drug interactions

Theophylline — ipriflavone increases theophylline levels significantly (CYP1A2 inhibition); monitor theophylline levels; reduce dose if combining.
Tolbutamide — case report of increased levels.
Warfarin — possible interaction; monitor INR.
Calcium supplements — used together; calcium absorption enhanced; not a problematic interaction.
Estrogenic medications — theoretical interaction via daidzein metabolite.
Pregnancy — limited safety data; avoid.

More Bone Health Ingredients

Bone Health
Calcium
Calcium is the most abundant mineral in the body — about 99% stored in bones and teeth, wi…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…
Bone Health
Ferrous Sulfate
Ferrous sulfate is the most common, cheapest, and longest-established oral iron form — rec…

Frequently asked questions about Ipriflavone

What is ipriflavone used for?

Ipriflavone is a synthetic isoflavone derivative used mainly for bone health, to support bone density (especially in postmenopausal women). Unlike soy isoflavones, it is not estrogenic but acts on bone metabolism.

Does ipriflavone help with bone density?

Some studies suggest ipriflavone may help maintain bone density, often used alongside calcium, though results are mixed and a large trial raised concerns. It is used for osteoporosis support but is not a first-line treatment.

How much ipriflavone should I take?

Studies commonly use about 600 mg per day (split into three 200 mg doses), usually with calcium. Follow product labeling and use it under medical guidance for bone goals.

Is ipriflavone safe?

It is generally tolerated, but one notable trial found it could lower white blood cell counts in some women, so periodic blood monitoring is advised with long-term use. It can also interact with some medications. Use it with a doctor's guidance.

What is Ipriflavone?

Ipriflavone is a synthetic isoflavone derivative (7-isopropoxyisoflavone) developed in the 1980s for osteoporosis. Distinguished from natural isoflavones by no significant estrogenic activity — bone effects without estrogenic concerns.

What is the recommended dosage of Ipriflavone?

The clinically studied dose is 600 mg/day in three divided doses (200 mg TID with meals) Always follow the product label and check with a healthcare provider for personal advice.

Is Ipriflavone safe, and does it have side effects?

For most healthy adults, Ipriflavone is well tolerated at studied doses. Reported effects can include: GI distress (most common — nausea, abdominal pain, dyspepsia). Lymphocyte reduction — IPRI study showed 13.2% incidence vs 4.0% placebo; reversible upon discontinuation; warrants monitoring. It may also interact with some medications. Ipriflavone is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Ipriflavone interact with any medications?

Possible interactions include: Theophylline — ipriflavone increases theophylline levels significantly (CYP1A2 inhibition); monitor theophylline levels; reduce dose if combining. Tolbutamide — case report of increased levels. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Ipriflavone?

NutraSmarts rates the evidence for Ipriflavone as Limited (2 out of 5). It is backed by 2 clinical trials and 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Adami S, Bufalino L, Cervetti R, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Serni U, Vecchiet L, Passeri M Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporosis International. 1997;7(2):119-25. doi: 10.1007/BF01623686.PubMedUsed to support: Human RCT showing ipriflavone (200 mg TID) significantly prevented radial bone loss over 2 years in postmenopausal women with low bone mass; supports Bone Mineral Density Support and Adjunct in Postmenopausal Bone Health benefits.
  2. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA. 2001;285(11):1482-8. doi: 10.1001/jama.285.11.1482.PubMedUsed to support: Large multicenter human RCT (474 women, 3 years) of ipriflavone 600 mg/day for postmenopausal osteoporosis; found no significant BMD benefit vs. placebo and noted lymphocytopenia adverse effect; essential citation for accurate, balanced representation of Bone Mineral Density Support (Mixed Evidence) benefit.